Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Invested Capital (2016 - 2026)

Aytu Biopharma has reported Invested Capital over the past 15 years, most recently at $16.1 million for Q4 2025.

  • Quarterly Invested Capital fell 53.83% to $16.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.1 million through Dec 2025, down 53.83% year-over-year, with the annual reading at $28.0 million for FY2025, 5.22% down from the prior year.
  • Invested Capital was $16.1 million for Q4 2025 at Aytu Biopharma, down from $38.0 million in the prior quarter.
  • Over five years, Invested Capital peaked at $153.8 million in Q2 2021 and troughed at $15.6 million in Q1 2021.
  • The 5-year median for Invested Capital is $39.5 million (2023), against an average of $55.4 million.
  • Year-over-year, Invested Capital tumbled 83.38% in 2021 and then surged 393.51% in 2022.
  • A 5-year view of Invested Capital shows it stood at $121.8 million in 2021, then crashed by 50.06% to $60.8 million in 2022, then plummeted by 44.29% to $33.9 million in 2023, then rose by 2.65% to $34.8 million in 2024, then tumbled by 53.83% to $16.1 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Invested Capital are $16.1 million (Q4 2025), $38.0 million (Q3 2025), and $28.0 million (Q2 2025).